Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) represent revolutionary personalized therapies for NSCLC patient, a subset of who carry specific EGFR mutations that are predictive of a favorable clinical response to EGFR-TKIs [1]–[3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.